News
The Future of Multiple Sclerosis – Time for a Change in Classification?
What are the latest findings on the etiopathogenesis of multiple sclerosis? Are they reflected in the current classification? And what will future therapy look like?
Protective Effect of SGLT2 Inhibitors on Heart Muscle Function - Findings from a Recent Meta-analysis
Sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) primarily offer the ability to…
Efficacy of Conventional and Intensified Lifestyle Interventions in Individuals with Prediabetes According to Risk Level
Lifestyle changes can prevent the development of type 2 diabetes in individuals with prediabetes,…
Metformin with Extended Release in the Treatment of Prediabetes
The benefit of metformin in preventing the development of diabetes in people with prediabetes has…
Meta-analysis of the Metabolic Effects of Second-generation Antipsychotics
Second-generation antipsychotics used in the therapy of schizophrenia exhibit varying metabolic…
Prevalence of Metabolic Syndrome During 1 Year After the First Episode of Psychosis
Portuguese authors elucidated the high prevalence of metabolic syndrome and adverse metabolic…
How Does Erdosteine Perform in Combination with Antibiotics?
Erdosteine is an oral mucoactive drug that reduces mucus viscosity by degrading disulfide bonds in…
Benefit of Adding Erdosteine to Maintenance Treatment of COPD
Erdosteine is a mucoactive drug with anti-inflammatory, antioxidant, and anti-adhesive effects…
ERS 2022: What Insights Do Studies Focused on COPD Biomarkers Bring?
In this year's scientific program of the international congress of the European Respiratory Society…
Specific treatment of pulmonary involvement in patients with AAT deficiency − why, how, and for whom?
For patients with emphysema and decreased lung function due to alpha-1-antitrypsin deficiency…